DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PEG-Intron (Peginterferon Alfa-2B) - Drug Interactions, Contraindications, Overdosage, etc



PEG-INTRON drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.


There is limited experience with overdosage. In the clinical studies, a few patients accidentally received a dose greater than that prescribed. There were no instances in which a participant in the monotherapy or combination therapy trials received more than 10.5 times the intended dose of PEG-Intron. The maximum dose received by any patient was 3.45 µg/kg weekly over a period of approximately 12 weeks. The maximum known overdosage of REBETOL was an intentional ingestion of 10 g (fifty 200 mg capsules). There were no serious reactions attributed to these overdosages. In cases of overdosing, symptomatic treatment and close observation of the patient are recommended.


PEG-Intron is contraindicated in patients with:

  • hypersensitivity to PEG-Intron or any other component of the product
  • autoimmune hepatitis
  • decompensated liver disease

PEG-Intron/REBETOL combination therapy is additionally contraindicated in:

  • patients with hypersensitivity to ribavirin or any other component of the product
  • women who are pregnant
  • men whose female partners are pregnant
  • patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017